COMERA LIFE SCIENCES HOLDING (CMRA) Stock Price, Forecast & Analysis
USA - NASDAQ:CMRA - US20037C1080 - Common Stock
CMRA Key Statistics, Chart & Performance
The current stock price of CMRA is 0.2227 USD. In the past month the price decreased by -16.28%. In the past year, price decreased by -83.38%.
CMRA Latest News, Press Relases and Analysis
CMRA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.68 | 412.01B | ||
| AMGN | AMGEN INC | 15.38 | 181.04B | ||
| GILD | GILEAD SCIENCES INC | 15.07 | 153.12B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.01 | 111.32B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.15 | 72.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 887.73 | 59.35B | ||
| INSM | INSMED INC | N/A | 41.09B | ||
| NTRA | NATERA INC | N/A | 28.75B | ||
| BIIB | BIOGEN INC | 9.65 | 23.67B | ||
| INCY | INCYTE CORP | 16.86 | 21.14B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.49 | 20.88B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 35.13 | 14.56B |
Related stock screener links
About CMRA
Company Profile
Comera Life Sciences Holdings, Inc. engages in developing medicines. The company is headquartered in Woburn, Massachusetts and currently employs 12 full-time employees. The company went IPO on 2020-12-15. The firm applies a knowledge of formulation science and technology to transform biologic medicines from intravenous (IV) to subcutaneous (SQ) forms. The firm is engaged in developing an internal portfolio of therapeutic product candidates using its proprietary formulation platform, SQore. Its proprietary formulation platform, SQore, is designed to transform biologic medicines from intravenous (IV) to subcutaneous (SQ) forms, optimize current versions of subcutaneous biologics, and produce biosimilar versions of existing subcutaneous products. Its product programs include CLS-001, a preclinical stage bio better for Crohn’s and Ulcerative Colitis disease, and CLS-002, a preclinical stage bio better for various oncology indications. The company also collaborates with pharmaceutical and biotechnology companies, applying the SQore platform to its partners’ biologic medicines to deliver enhanced SQ formulations.
Company Info
COMERA LIFE SCIENCES HOLDING
12 Gill Street, Suite 4650
Woburn MASSACHUSETTS US
Employees: 12
Phone: 16178712101.0
COMERA LIFE SCIENCES HOLDING / CMRA FAQ
Can you describe the business of COMERA LIFE SCIENCES HOLDING?
Comera Life Sciences Holdings, Inc. engages in developing medicines. The company is headquartered in Woburn, Massachusetts and currently employs 12 full-time employees. The company went IPO on 2020-12-15. The firm applies a knowledge of formulation science and technology to transform biologic medicines from intravenous (IV) to subcutaneous (SQ) forms. The firm is engaged in developing an internal portfolio of therapeutic product candidates using its proprietary formulation platform, SQore. Its proprietary formulation platform, SQore, is designed to transform biologic medicines from intravenous (IV) to subcutaneous (SQ) forms, optimize current versions of subcutaneous biologics, and produce biosimilar versions of existing subcutaneous products. Its product programs include CLS-001, a preclinical stage bio better for Crohn’s and Ulcerative Colitis disease, and CLS-002, a preclinical stage bio better for various oncology indications. The company also collaborates with pharmaceutical and biotechnology companies, applying the SQore platform to its partners’ biologic medicines to deliver enhanced SQ formulations.
Can you provide the latest stock price for COMERA LIFE SCIENCES HOLDING?
The current stock price of CMRA is 0.2227 USD. The price decreased by -8.88% in the last trading session.
What is the dividend status of COMERA LIFE SCIENCES HOLDING?
CMRA does not pay a dividend.
What is the ChartMill technical and fundamental rating of CMRA stock?
CMRA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
How is the valuation of COMERA LIFE SCIENCES HOLDING (CMRA) based on its PE ratio?
COMERA LIFE SCIENCES HOLDING (CMRA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.59).
How many employees does COMERA LIFE SCIENCES HOLDING have?
COMERA LIFE SCIENCES HOLDING (CMRA) currently has 12 employees.
CMRA Technical Analysis
CMRA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CMRA. CMRA has a bad profitability rating. Also its financial health evaluation is rather negative.
CMRA Financial Highlights
Over the last trailing twelve months CMRA reported a non-GAAP Earnings per Share(EPS) of -0.59. The EPS increased by 13.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -439.19% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |